Back to catalogue
№ 292 20 filings · 2021-08-03 → 2026-07-20

PULSAR GROUP PLC

PULS
Technology Share price 24.00p Market cap £33m Overall fit 500 /1000

Partial fit for the strategy: cheap vertical SaaS with genuine AI product refresh and operating leverage, but AI is not yet driving revenue growth, earnings quality is weak (heavy capitalisation, statutory losses) and it's a small-cap AIM name with competitive intensity.

Fair value range 40p–60p Mid case · £68m
Absolute upside +109% vs current market cap
Conviction 3/5 confidence in undervalued call
Supports the call
  • High recurring revenue mix (97%) with clear ARR disclosure
  • Refinancing removes balance sheet overhang
  • Multiple valuation methods converge on 40-65p range
Limits the call
  • Adjusted EBITDA overstates cash economics due to £6m/yr capitalised development
  • Underlying constant-currency ARR growth only ~2% — AI products not yet material to top line
Methodology

Blended EV/ARR and EV/adjusted EBITDA with FCF cross-check

In one line · bull case

Deep-value AI-native vertical SaaS at 0.6x ARR with 97% recurring revenue, expanding margins, refinanced balance sheet and demonstrable operating leverage — priced for continued growth disappointment that may not materialise.

In one line · biggest risk

Underlying ARR growth is only ~2% at constant currency and AI-product traction has yet to translate into meaningful top-line acceleration — the cheap multiple may prove a value trap if growth stays stuck.

Drivers
AI beneficiary 50 /100
Vertical marcomms SaaS with AI-native products (Lumina, Saga, TeamMates) — legitimate AI receiver but AI has not yet translated into material ARR uplift.
Operating leverage 70 /100
High fixed-cost software model — H1 2026 showed ~60% incremental contribution margin; a 10-20% revenue beat plausibly delivers 50%+ EBITDA beat.
Earnings vs expectations 55 /100
Broadly in-line delivery across periods with modest FY24 EBITDA beat; no profit warnings but external consensus disclosure is thin.
Growth momentum 40 /100
Constant currency ARR growth only £1.2m in H1 2026 on £64m base (~2% annualised); reported revenue growth of 10% flattered by AUD/USD tailwinds.
Moat 40 /100
Customer switching costs and workflow embedment provide some stickiness, but market is competitive (Cision, Meltwater, Brandwatch) with no dominant moat.
Earnings quality 30 /100
Persistent statutory losses (£9.6m FY25), heavy capitalisation of development costs (£6m/yr vs ~£5m amortisation), adjusted EBITDA excludes recurring 'non-recurring' items.
Management quality 55 /100
Executed £7m+ annualised cost reduction and completed refinancing; Isentia integration mixed but stabilised; LTVCP incentives aligned with shareholder value creation.
Cyclicality 40 /100
Marcomms budgets are cyclical but 97% recurring revenue with mission-critical intelligence tools cushions the impact.
Leverage 35 /100
Net debt £6m against £10m adjusted EBITDA (~0.6x) — refinanced April 2026 into 3-year £8m HSBC facility; manageable but not fortress.
Value-trap signals · 6
  • Constant-currency ARR growth only ~2% despite AI narrative
  • Persistent statutory losses (£6.6m FY23, £6.6m FY24, £9.6m FY25)
  • Heavy capitalisation of development costs masks true earnings power
  • APAC constant-currency ARR declined in H1 2026
  • Share price down 42% from 12-month peak, AIM small-cap illiquidity
  • Historical equity raises at depressed prices (£2.9m at 38p in May 2025)

PULSAR GROUP PLC (PULS) — Investment Research Note

Executive summary

Pulsar Group is a UK-listed AIM-quoted SaaS provider of audience intelligence, media monitoring and social listening tools for the PR, communications and marketing industries, serving ~6,000 organisations across EMEA/NA (Vuelio, Pulsar brands) and APAC (Isentia brand, acquired 2021). Across the period covered, revenue grew from £33m (FY21) to £61m (FY25) largely via the Isentia acquisition, ARR growth accelerated modestly to +£3.9m constant currency in FY25 and adjusted EBITDA margins expanded from ~11% to 17% as management executed a £7m+ annualised cost reduction programme; H1 2026 delivered 10% revenue growth and 39% adjusted EBITDA growth 2026-07 interim. The single most important valuation point today: at 28p the shares trade at ~0.6x ARR and ~4-5x forward adjusted EBITDA — cheap for a 97% recurring-revenue SaaS business, but the discount reflects genuine concerns around slow underlying growth, statutory losses (£9.6m FY25), heavy capitalised development (£6m/yr) and thin free cash flow.

Fair value estimate

  • Fair value range: 40p – 60p per share
  • Implied market cap range: £54m – £81m (vs current £42m)
  • Absolute upside: +43% to +114%, mid-point ~50p / £68m / +79%

Methodology: Blended EV/ARR and EV/EBITDA multiples cross-checked against forward FCF.

  • EV/ARR: ARR of £67.2m at May 2026. Peer SaaS trades 1.5-3x; applying a discounted 1.0-1.5x for slow growth and AIM discount → EV £67-101m → equity 44-70p.
  • EV/adjusted EBITDA: FY26E adjusted EBITDA of ~£11-12m (FY25 £10.4m + partial-year benefit of continuing cost actions). At 5-8x → EV £55-96m → equity 36-66p.
  • FCF cross-check: Adjusted EBITDA (£10.4m) less capitalised dev (£6m), non-recurring (£3m normalising down), lease payments (£1.3m), interest (£1.1m), tax (£0.2m) ≈ £(1)m to +£3m current-run-rate FCF. Not overwhelming; supports a discount to headline EBITDA multiples.

Central case ~50p assumes the cost transformation sticks, growth stays low-single-digit, and market rewards the SaaS profile with a 1.2x ARR multiple. Current 28p implies the market expects further churn/growth disappointment.

Sector context

Sector classification (Technology / Software — vertical SaaS for marcomms) is confirmed. Pulsar sits below typical software peers on growth and quality (revenue growth mid-single-digit vs 15-25% for scaling SaaS; persistent statutory losses; capitalised dev >amortisation is normalising but drags reported margins) but cheaper on multiples. Comparable listed peers: Cision (private since 2020), Meltwater (Oslo-listed, went private 2024), Brandwatch (owned by Cision), GlobalData (LSE:DATA, but broader), Kin + Carta / dotDigital as UK-listed AIM/main-market marcomms tech comparators. Pulsar's small size (£42m mcap) means it screens far cheaper than global peers.

Investment thesis

  1. Deep-value SaaS at ~0.6x ARR with 97% recurring revenue and improving margins. ARR £67.2m, adj EBITDA margin has moved from 12% (H1 2025) to 15% (H1 2026) with management guiding further cost reduction by FY26 year-end 2026-07 interim. Sustainable operating leverage is now visible.
  2. AI-native product refresh (Lumina, Saga, Narratives AI, CLEAR, TeamMates) expands the addressable use case for existing enterprise customers. Enterprise standardisation deals (Aldi Nord, Coca-Cola, Diageo, IAG, Manchester United won in H1 2026) show demand for AI-augmented marcomms intelligence 2026-07 interim.
  3. Balance sheet risk materially reduced. Refinanced in April 2026 into a 3-year £8m HSBC facility (£6m loan + £2m RCF), net debt £6m vs FY25 £5.6m, cash generation up sharply (net cash from operations £3.3m in H1 vs £1.8m) 2026-07 interim. Removes the going-concern overhang.

Key risks

  1. Underlying ARR growth is weak — £1.2m constant currency in H1 2026 on a £64m base (~2% annualised). Reported growth flattered by AUD/USD tailwinds; APAC constant-currency ARR actually declined £0.2m in H1 2026 2026-07 interim. AI narrative isn't yet translating into material top-line uplift.
  2. Earnings quality is weak: £6m/yr capitalised development, adjusted EBITDA excludes £2.7m non-recurring in H1 2026 alone and reported statutory loss was £9.6m in FY25. True cash-generative earnings power is a fraction of headline adjusted EBITDA 2026-05 final results.
  3. Competitive pressure from larger, better-capitalised private peers (Cision, Meltwater, Brandwatch) plus new gen-AI entrants could compress pricing or force further R&D spend. FTE has dropped 23% (918→710) — the business is being run leaner, but there's little margin for a sales execution stumble 2026-05 final results, "inferred".

Operating leverage

The business has meaningful — but not extreme — operating leverage. Cost base is ~£29m recurring admin expenses on £61m revenue with a further ~£19m cost of sales; gross margin sits at 65-69%. The recent proof point: H1 2026 delivered £2.9m of extra revenue, of which £2.1m was organic (constant currency), which flowed into £1.3m of extra adjusted EBITDA (constant currency) — an incremental EBITDA contribution margin of ~60% 2026-07 interim. Management explicitly guides that "the overall cost base is expected to reduce further" and margin expansion should continue. If revenue grew 10-20% above current expectations without adding proportional cost, adjusted EBITDA could plausibly rise from £10m to £15-18m — i.e. a 15% revenue beat could deliver a 50%+ EBITDA beat. The fixed R&D commitment (£6m/yr capitalised + £1.5m expensed) and largely fixed data-licensing infrastructure are the structural anchors of this leverage. Constraint: gross margin declined to 65% in H1 2026 from 69% (mix of higher cost-of-sales items), so leverage is not automatic — it has to come from opex discipline.

Value-trap signals

  • ARR growth of only ~2% constant currency at group level despite the "AI-driven inflection" narrative.
  • Repeated years of statutory losses (£6.6m, £6.6m, £9.6m FY23/24/25); persistent loss-making at operating line.
  • Heavy capitalisation of development costs — if expensed, adjusted EBITDA would drop from £10.4m to ~£4m FY25.
  • Small-cap AIM listing, thin trading liquidity; share price down 42% from 12-month peak (48.5p → 28p).
  • APAC growth stalled on a constant-currency basis; reported ARR growth largely FX-driven.
  • Historical dilutive equity raises (£2.9m at 38p in May 2025).

Earnings vs. expectations

Guidance disclosure is limited to "in line with the Board's expectations" language and one broker consensus reference (Cavendish). Where visible: FY24 adjusted EBITDA came in at £9.3m (Jan 2025 trading update anticipated ~£9.0m vs consensus £9.2m — a modest beat); FY25 adjusted EBITDA £10.4m was "slightly ahead of consensus £6.7m" per Feb 2026 trading update — the consensus number appears understated so hard to read as a genuine beat; H1 2026 was reported "in line with the Board's expectations". Pattern: broadly in-line-to-slightly-ahead delivery with no visible profit warnings, though disclosure quality on external consensus is thin and the company reports on its own adjusted metrics.

Conviction

Conviction: 3 (moderate). Anchoring factors: (1) revenue base is highly recurring and well-disclosed (97% recurring, ARR broken out by region and constant currency); (2) refinancing removes near-term balance sheet risk; (3) multiple valuation approaches converge on 40-65p. Limiting factors: (1) adjusted EBITDA overstates cash economics because of £6m/yr capitalised dev — true FCF power is genuinely uncertain and the fair value could be materially lower if capitalisation policies proved aggressive on audit; (2) growth trajectory is weak and I cannot confidently model whether AI-product traction accelerates ARR growth to 8-10% or leaves it stuck at 2-3%.

Driver scoring rationale

Overall score anchored around ~500 — this is a "partial fit" for the investor profile. The AI angle is real but not yet a material revenue driver; operating leverage is present; valuation is cheap; downside is contained but the business has quality concerns (heavy capitalisation, statutory losses, competitive intensity).

Filings consulted · 28

Every document the LLM read for this note. Click any row to open the source.

  1. 2026-07-20Interim Results2026-07-20_9675770_interim-results.md0.90
  2. 2026-05-07Posting OF Annual Report And Notice OF Agm2026-05-07_9557637_posting-of-annual-report-and-notice-of-agm.md0.95
  3. 2026-05-01Final Results For The Year Ended 30 November 20252026-05-01_9547975_final-results-for-the-year-ended-30-november-2025.md1.00
  4. 2026-02-20Trading Update2026-02-20_9439230_trading-update.md0.85
  5. 2025-07-14Interim Results2025-07-14_8976634_interim-results.md0.58
  6. 2025-05-08Result OF Placing Related Parties Amp Tvr2025-05-08_8866548_result-of-placing-related-parties-amp-tvr.md0.46
  7. 2025-05-07Proposed Placing2025-05-07_8866204_proposed-placing.md0.46
  8. 2025-05-01Final Results For The Year Ended 30 November 20242025-05-01_8855707_final-results-for-the-year-ended-30-november-2024.md0.65
  9. 2025-01-24Trading Update2025-01-24_8703979_trading-update.md0.55
  10. 2024-12-02Disposal2024-12-02_8582911_disposal.md0.49
  11. 2024-07-08Interim Results2024-07-08_8297981_interim-results.md0.41
  12. 2024-05-24Final Results For The Year Ended 30 November 20232024-05-24_8219086_final-results-for-the-year-ended-30-november-2023.md0.45
  13. 2024-05-09Posting OF Notice OF Agm2024-05-09_8184254_posting-of-notice-of-agm.md0.14
  14. 2024-04-16Proposed Change OF Name2024-04-16_8138862_proposed-change-of-name.md0.27
  15. 2024-01-16Trading Update2024-01-16_7990488_trading-update.md0.38
  16. 2023-07-04Interim Results2023-07-04_7610860_interim-results.md0.23
  17. 2023-06-22Trading Update2023-06-22_7587575_trading-update.md0.21
  18. 2023-04-21Posting OF Notice OF Agm2023-04-21_1241_posting-of-notice-of-agm.md0.07
  19. 2023-04-21Posting OF Notice OF Agm2023-04-21_7494469_posting-of-notice-of-agm.md0.07
  20. 2023-04-17Final Results For The Year Ended 30 November 20222023-04-17_7491789_final-results-for-the-year-ended-30-november-2022.md0.25
  21. 2022-12-13Trading Update2022-12-13_7407002_trading-update.md0.21
  22. 2022-07-05Interim Results2022-07-05_6869820_interim-results.md0.23
  23. 2022-06-17Trading Update2022-06-17_6981689_trading-update.md0.21
  24. 2022-04-29Posting OF Notice OF Agm2022-04-29_7139502_posting-of-notice-of-agm.md0.07
  25. 2022-04-25Final Results For The Year Ended 30 November 20212022-04-25_7039599_final-results-for-the-year-ended-30-november-2021.md0.25
  26. 2022-01-17Trading Update2022-01-17_6856669_trading-update.md0.21
  27. 2021-09-02Completion OF Acquisition And RE Admission2021-09-02_6716930_completion-of-acquisition-and-re-admission.md0.19
  28. 2021-08-03Fundraising Timetable Update2021-08-03_6819142_fundraising-timetable-update.md0.07

This research note was authored by a large language model after reading 20 regulatory filings published between 2021-08-03 and 2026-07-20. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.